1μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
Synonyms | ABBV-085, PR-1498487-MMAE, PR-1498487, Samrotamab vedotin |
Expression System | CHO |
Molecular Weight | 23-25kDa&47-53kDa (Reducing) |
Purity | >95% by SDS-PAGE |
Conjugation | Unconjugated |
Tag | No Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, PH7.4, 5% trehalose |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. |
Reference | 1.Galvan M, Boer R, Schudt C. Interaction of telenzepine with muscarinic receptors in mammalian sympathetic ganglia. Eur J Pharmacol. 1989 Aug 11;167(1):1-10. |
Background
Samrotamab (PR-1498487) is a humanized anti-LRRC15 antibody that can be used to synthesize the ADC compound (Samrotamab vedotin). It is a humanized IgG1-κ chimeric antibody targeting LRRC15.
Picture
Picture
SDS-PAGE
ELISA
Immobilized LRRC15/LIB His Tag, Human (Cat. No. UA010915) at 10.0μg/mL (100μL/well) can bind Samrotamab (Cat. No. UA011138) with EC50 of 6.86-9.73ng/mL.
